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Aims. To determine the progression of body weight (BW) and body composition (BC) in patients with type 2 diabetes mellitus
(T2D) on insulin therapy and the consequences on muscle strength (MS) as a reﬂect of free fat mass increases. Research design and
methods. We analysed BC using air displacement plethysmography and MS by hand grip dynamometry in 40 T2D before and after
three (M3) and six months (M6) of insulin therapy. Results. at baseline HbA1c was 9.76 ±1.6% and BW was stable with fat mass
(FM) 28 ± 10.7kg; and fat free mass (FFM) 52.4 ± 11kg; at M6, HbA1c improved to 7.56 ± 0.8%; insulin doses tended to increase.
BW gain at M6 was + 3.2 ± 4.2kg and with an increase of only 25% by M3; it was composed of FM, whereas FFM was unchanged.
MS did not increase on insulin therapy. Conclusions. In T2D, BW gain was composed exclusively of FM with no improvement in
MS.
1.Introduction
Insulin is a major therapeutic tool for insulin-deﬁcient
patients with type 1 diabetes mellitus, and also for patients
with type 2 diabetes mellitus (T2D), with both insulin
resistance and a relative insulin deﬁciency [1]. Its eﬀects
on glucose metabolism are well known, but insulin also
inﬂuences lipid and protein metabolism with anabolic and
anticatabolic eﬀe c t s .T h e s eh a v eb e e nl e s ss t u d i e dd e s p i t e
body weight (BW) gain being an important consequence of
insulin therapy, identiﬁed in both the DCCT [2] and UKPDS
[3] studies. BW gain is probably a beneﬁt in purely insulin-
deﬁcient patients in whom lack of insulin is responsible for
lean tissue loss [4], but in T2D the worsening of existing
obesity seems undesirable.
Analysis of body composition (BC) changes can help
determine whether insulin-induced BW gain can be consid-
ered as beneﬁcial or not, by distinguishing the accumulation
of fat (FM) from that of fat-free mass (FFM). FFM is an
important nutritional parameter, linked with immune com-
petence, functional status, and survival [5]. Previous studies
on the inﬂuence of insulin therapy on BC of patients with
diabetes mellitus have been limited because the methods for
analyzing BC (tritiated water, underwater weighing or four-
compartment model) are diﬃcult to use in clinical practice.
Air displacement plethysmography is a new, safe, quick,
and valid technique, providing accurate measurements of
body density [6] and discriminating moderate changes in
FM and FFM [7]. Although some uncertainties due to
the hydration of FFM may inﬂuence any two-compartment
model-based analysis [8], the simultaneous measurement
of muscle strength (MS) by dynamometry can be used to
conﬁrm the results of FFM: a correlation between FFM and
MS has been previously demonstrated [9–11]
The aim of our study was to assess the eﬀects of insulin
therapy on body weight and composition, and on muscular
strength, in T2D with failure to oral hypoglycaemic agents.
2.SubjectsandMethods
2.1. Patients. 40 type 2 diabetic patients (18 men and 22
women) who presented secondary failure to oral antidiabetic
agents with HbA1c > 7% after a duration of 13.5 ± 8.7
years of diabetes mellitus were recruited during their stay
in our department. The only inclusion criterion was the
introductionofinsulin.Exclusioncriteriaincludedareduced2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
autonomy, which could interfere with the plethysmographic
measurement, and any condition leading to water and salt
retention or any severe concurrent illness.
All T2D were treated with insulin injections and their
oral antidiabetic agents. All patients monitored their blood
glucose and were asked to adapt the insulin doses in order to
obtain HbA1c close to recommended levels [12]. They were
advised during their hospitalization about diet and physical
activity.
All patients were fully informed of the purpose of the
study and gave their informed consent to take part in
the investigation. The university hospital ethics committee
accepted the protocol.
2.2. Study Design. At baseline, all patients underwent a
physical and laboratory examination to rule out any under-
current disease. When insulin therapy was indicated, the
patients were invited to participate in the study and all
accepted. We carried out BC analysis and MS measurements
at baseline, then 3 and 6 months later. The baseline analysis
was conducted just before starting insulin.
2.3. Analytical Methods. HbA1c was measured on EDTA
Vacutainer samples by aﬃnity chromatography using a Hi-
AUTOA1c analyzer (A Menarini Diagnostics, Antony Cedex,
France) initially and 3 and 6 months later.
BW was measured on an electronic scale to the nearest
0.1 kg and height to the nearest 0.1 cm. Waist circumference
(WC) at the umbilical midline was measured to the nearest
mm with ﬂexible tape.
Air displacement plethysmographic measurements were
carried out using the Bod-Pod body composition system
(Life Measurement, Inc, Concord, Calif, USA) according to
the manufacturer’s recommendations [13]. The procedure
involved the calibration of the system when empty and
then when a 49.771-liter metal cylinder was placed inside.
After being weighed on an electronic scale, the patients, in
their undergarments and wearing a swimming cap, were
seated inside the chamber and asked to remain with hands
positioned on their thighs and breathing normally. Body
volume was assessed by the diﬀerence between the volume
of air inside the chamber when empty and then with the
subject present. If two consecutive measurements of volumes
diﬀered from each other by more than 150mL, a third
measurement was conducted. Body density was calculated as
Body Weight/Body Volume and fat mass was calculated from
the Siri equation (%FM = (4.950/Body density)-4.500)×100
[14]. Predicted respiratory volumes were taken into account
in the calculations.
Three consecutive measurements of handgrip strength
with the dominant hand were performed with a calibrated
dynamometer (Takei Scientiﬁc Instruments, Tokyo, Japan),
w h i c hw a sr e s e tt oz e r ob e f o r ee a c hm e a s u r e m e n t .T h em e a -
surements were conducted under standardized conditions:
subject seated, the shoulder adducted and neutrally rotated,
with the elbow at 90◦ ﬂexion and the forearm and wrist in a
neutral position. Patients were encouraged using a standard
Table 1: Evolution from M0 to M6 of body parameters and
Hb1Ac levels during insulin therapy in patients with type 2 diabetes
mellitus. Results are mean (SD), P indicates the signiﬁcance of the
diﬀerence versus the baseline value (NS: nonsigniﬁcant).
3m o n t h s
(M3)
6m o n t h s
(M6)
Weight change (kg) + 0.7 (2.3) + 3.1 (2.2)
P<. 008
Fat mass change (kg) − 0 .2 (3.1) + 3.1 (2.7)
P<. 012
Waist circumference change (cm) −0.3 (3.8) + 1.7 (4.5)
P<. 004
Fat free mass change (kg) + 0.9 (2.9)
P = .15 (NS)
− 0.1 (2.6)
P = .82 (NS)
Muscle strength change (kg) + 0.4 (2.9)
P = 0.57
+ 0.4 (4.2)
P = .87
HbA1c change (%)
− 2.4 (1.7)
P<0.0005
− 2.2 (1.7)
P<. 0005
Insulin doses (U/kg) 0.41 (0.32) 0.44 (0.27)
phraseology (squeeze the handle as hard as possible). Mean
values were recorded.
2.4. Statistical Analysis. Data are shown as means with
standard deviations. SPSS software 10.0.5 was used for
the calculations (standard version, copyright ´ OS P S SI n c .
1989–1999). A one-way analysis of variance for repeated
measures over time (ANOVA) was used to compare the
values atbaseline (M0),3 months (M3),and 6 months (M6).
Associations were tested by linear regression. P<. 05 was
considered signiﬁcant.
3. Results
3.1. Baseline. The T2D were 62 ± 12 years, their BW was
stable over the previous three months: BW 85.4 ± 14.7kg:
BMI 30.9 ± 5.7kg/m2, with high FM 28 ± 10.7kg, and WC:
105.7 ± 12cm,. FFM was 52.4 ± 11kg; and MS was 29.1 ±
8.2kg; Glycaemic control was poor: HbA1c 9.76 ± 1.6%.
3.2. Progression With Insulin Therapy (Table 1).
Glycaemic Control and Insulin Doses. HbA1C improved
during the ﬁrst three months, and then stabilized. M6
HbA1c: 7.56 ± 0.8%. The doses of insulin tended to increase
from M0 to M6.
Body Weight and Composition. BW increased on insulin
treatment to 88.5 ± 14kg, and 75% of the increase occurred
after 3 months. The composition of the BW gain: during the
ﬁrst three months FM and FFM were unchanged, but at six
months, FM increased ( P<. 012(M6/M0))whereas FFM
remained unchanged, BW gain was related to changes in FM
(r = 0.83, P<. 0005) and WC (r = 0.81, P<. 0005), but
not to those of FFM(r = 0.12, P = .63). BW gain was related
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in HbA1c (r =− 0.61, P = .007), and to the insulin doses
(r = 0.81, P<. 0005) in T2D.
3.3. Muscle Strength. MS was correlated with FFM (r = 0.72,
P<. 0005) and inversely correlated with FM (r =− 0.52,
P = .001). MS remained stable and did not increase during
the six months.
4. Discussion
In this study, we studied the progression of BW, BC, and
MS during six months after starting insulin therapy in 40
T2D. Insulin induced a signiﬁcant decrease in HbA1C, that
approached the recommended level in type 2 diabetes (7.5±
0.9%). The course and nature of the BW gain was +3.1 ±
2.2kg at M6 and 75% of the increase occurred after M3.
All the weight gain was due to FM (+3.1 ± 2.7kg), whereas
FFM was unchanged (−0.1 ± 1.6kg) and T2D did not gain
MS on insulin therapy. The BW gain at M6 was correlated
with initial HbA1c and insulin doses and with the decrease
in HbA1C.
One limitation of our study stems from the use of
a two-compartment model for the analysis of BC by air
displacement plethysmography (ADP), as hydration of FFM
cannot be assumed to be constant during insulin therapy.
Overall our results are in agreement with previous studies.
In T2D, previous studies reported that BW gain (+1.6 ±
4 . 9t o+ 5 . 2± 2.7kg at six months) was mainly composed
of fat [15–20]. We conﬁrm the predominance of FM gain
in insulin-treated T2D as it represented the entire BW gain;
we demonstrated for the ﬁrst time the absence improvement
in MS after insulin therapy in type2 diabetic patients that
conﬁrm the absence of improvement in FFM during weight
gain in insulin treated T2D. Higher MS in type 1 diabetic
patients versus T2D has been reported by Cetinus et al.,
as compared to age-matched control subjects [21]. The
correlation between the decrease in HbA1c and BW gain,
and with insulin doses have been reported by other authors
[18, 20].
Our study did not aim to explain the progression of BC
duringinsulintreatment,butseveralstudiesinvestigatingthe
role of insulin on protein metabolism in diabetes mellitus
have provided useful data. In type 1 diabetes, protein
turnoverstudiesusingisotopicallylabeledaminoacidtracers
have demonstrated that protein breakdown and amino acid
oxidation are increased in the insulin-deprived state, and are
normalized by insulin, which has an anticatabolic eﬀect [4].
The eﬀect of insulin on protein synthesis is more diﬃcult to
exploreandamatterofdebate:intype2diabeticpatients,the
eﬀect of acute administration of insulin on suppression of
muscle protein breakdown was noted [22], but a resistance
to insulin action develops on chronic administration [23];
a reduced nutritive blood ﬂow may be involved in the
resistance of muscular protein synthesis to the action of
insulin in type 2 diabetic patients ; indeed, the response
of muscle protein synthesis is impaired in the elderly [24],
due to the inability of insulin to increase vasodilatation
[22]; adiposity is also associated with a reduced whole-body
protein anabolic action of insulin in women [25] and the
elderly [26]. So in type 2 diabetic patients, insulin therapy
can be without any eﬀect on FFM and consequently on MS.
Insulin therapy is clearly beneﬁcial for glycemic control
in T2D but we do not feel that the gain in FM oﬀsets this
beneﬁt. However, the excess fat is deposited essentially in the
intra-abdominal area [20]. Although we did not use DEXA
to determine the distribution of FM gain, we observed an
increaseinWC,whichisagoodindicatorofvisceralFM[27].
The long-term consequences of these nutritional changes
need to be determined.
In summary, BW gain of TD2 on insulin therapy was 3.1
± 2.2kg, it was predominantly fat with no improvement in
muscular strength or FFM.
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